MK-6592

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-6592, covering 2016-11-29 to 2016-11-29. Get the full timeline:

Most recent: Clinical Trial Update: Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) [Phase 1]